ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced two executive appointments: Robert Kaper, M.D., has joined ACADIA as Senior Vice President, Global Head of Medical Affairs, and Eliseo Salinas, M.D., M.Sc., has joined the company as Senior Vice President, Chief Scientific Officer and H

Full Story →